Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2013

01-04-2013 | Review

Cachexia in chronic heart failure: endocrine determinants and treatment perspectives

Authors: Norman Mangner, Yae Matsuo, Gerhard Schuler, Volker Adams

Published in: Endocrine | Issue 2/2013

Login to get access

Abstract

It is well documented in the current literature that chronic heart failure is often associated with cachexia, defined as involuntary weight loss of 5 % in 12 month or less. Clinical studies unraveled that the presence of cachexia decreases significantly mean survival of the patient. At the molecular level mainly myofibrillar proteins are degraded, although a reduced protein synthesis may also contribute to the loss of muscle mass. Endocrine factors clearly regulate muscle mass and function by influencing the normally precisely controlled balance between protein breakdown and protein synthesis The aim of the present article is to review the knowledge in the field with respect to the role of endocrine factors for the regulation of cachexia in patients with CHF and deduce treatment perspectives.
Literature
1.
W.J. Evans, J.E. Morley, J. Argiles, C. Bales, V. Baracos, D. Guttridge, A. Jatoi, K. Kalantar-Zadeh, H. Lochs, G. Mantovani, D. Marks, W.E. Mitch, M. Muscaritoli, A. Najand, P. Ponikowski, F. Rossi Fanelli, M. Schambelan, A. Schols, M. Schuster, D. Thomas, R. Wolfe, S.D. Anker, Cachexia: a new definition. Clin. Nutr. 27, 793–799 (2008)PubMedCrossRef
2.
3.
S.D. Anker, P. Ponikowski, S. Varney, T.P. Chua, A.L. Clark, K.M. Webb-Peploe, D. Harrington, W.J. Kox, P. Poole-Wilson, A.J.S. Coats, Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050–1053 (1997)PubMedCrossRef
4.
W.E. Mitch, A.L. Goldberg, Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897–1905 (1996)PubMedCrossRef
5.
P.O. Hasselgren, J.E. Fischer, Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann. Surg. 233, 9–17 (2001)PubMedCrossRef
6.
H.L. Eley, S.T. Russell, M.J. Tisdale, Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem. J. 407, 113–120 (2007)PubMedCrossRef
7.
K. Lenk, G. Schuler, V. Adams, Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle 1, 9–21 (2010)PubMedCrossRef
8.
M. Brink, A. Anwar, P. Delafontaine, Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int. J. Cardiol. 85, 111–121 (2002)PubMedCrossRef
9.
P. Costelli, P. Reffo, F. Penna, R. Autelli, G. Bonelli, F.M. Baccino, Ca2+-dependent proteolysis in muscle wasting. Int. J. Biochem. Cell Biol. 37, 2134–2146 (2005)PubMedCrossRef
10.
S.H. Lecker, R.T. Jagoe, A. Gilbert, M. Gomes, V.E. Baracos, J. Bailey, S.R. Price, W.E. Mitch, A.L. Goldberg, Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004)PubMedCrossRef
11.
M.T. Pepato, R.H. Migliorini, A.L. Goldberg, I.C. Kettelhut, Role of different proteolytic pathways in degradation of muscle protein from streptozotocin-diabetic rats. Am. J. Physiol. Endocrinol. Metab. 271, E340–E347 (1996)
12.
T.N. Sato, Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70–74 (1995)PubMedCrossRef
13.
A. Yndestad, J.K. Damas, E. Oie, T. Ueland, L. Gullestad, P. Aukrust, Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 9, 236–241 (2007)PubMedCrossRef
14.
D. Hasper, M. Hummel, F.X. Kleber, I. Reindl, H.D. Volk, Systemic inflammation in patients with heart failure. Eur. Heart J. 19, 761–765 (1998)PubMedCrossRef
15.
S. Anker, A.L. Clark, M. Kemp, C. Salsbury, M.M. Teixeira, P.G. Hellewell, A.J.S. Coats, Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol. 30, 997–1001 (1997)PubMedCrossRef
16.
M. Rauchhaus, V. Koloczek, H. Volk, M. Kemp, J. Niebauer, D.P. Francis, A.J. Coats, S.D. Anker, Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int. J. Cardiol. 76, 125–133 (2000)PubMedCrossRef
17.
B. Levine, J. Kalman, L. Mayer, H.M. Fillit, M.P. Packer, Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236–241 (1990)PubMedCrossRef
18.
M. Rauchhaus, W. Doehner, D.P. Francis, C. Davos, M. Kemp, C. Liebenthal, J. Niebauer, J. Hooper, H.D. Volk, A.J.S. Coats, S.D. Anker, Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102, 3060–3067 (2000)PubMedCrossRef
19.
A. Deswal, N.J. Petersen, A.M. Feldman, J.B. Young, B.G. White, D.L. Mann, Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103, 2055–2059 (2001)PubMedCrossRef
20.
C. Cappuzzello, L. Di Vito, R. Melchionna, G. Melillo, L. Silvestri, E. Cesareo, F. Crea, G. Liuzzo, A. Facchiano, M. Capogrossi, M. Napolitano, Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-gamma in patients with chronic heart failure. J. Transl. Med. 9, 28–34 (2011)PubMedCrossRef
21.
M. Niethammer, M. Sieber, S. von Haehling, S.D. Anker, T. Munzel, G. Horstick, S. Genth-Zotz, Inflammatory pathways in patients with heart failure and preserved ejection fraction. Int. J. Cardiol. 129, 111–117 (2008)PubMedCrossRef
22.
C. Garcia-Martinez, F.J. Lopez-Soriano, J.M. Argiles, Acute treatment with tumor necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle. Mol. Cell. Biochem. 125, 11–18 (1993)PubMedCrossRef
23.
Y.P. Li, R.J. Schwartz, I.D. Waddell, B.R. Holloway, M.B. Reid, Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-+¦B activation in response to tumor necrosis factor alpha. FASEB J. 12, 871–880 (1998)PubMed
24.
25.
S. Acharyya, K.J. Ladner, L.L. Nelsen, J. Damrauer, P.J. Reiser, S. Swoap, D.C. Guttridge, Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114, 370–378 (2004)PubMed
26.
J. Cheng, K. Turksen, Q.C. Yu, H. Schreiber, M. Teng, E. Fuchs, Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. Genes Dev. 6, 1444–1456 (1992)PubMedCrossRef
27.
V. Adams, N. Mangner, A. Gasch, C. Krohne, S. Gielen, S. Hirner, H.J. Thierse, C.C. Witt, A. Linke, G. Schuler, S. Labeit, Induction of MuRF1 is essential for TNF-[alpha]-induced loss of muscle function in mice. J. Mol. Biol. 384, 48–59 (2008)PubMedCrossRef
28.
A. Oliff, D. Defeo-Jones, M. Boyer, D. Martinez, D. Kiefer, G. Vuocolo, A. Wolfe, S.H. Socher, Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50, 555–563 (1987)PubMedCrossRef
29.
K.A. Baltgalvis, F.G. Berger, M.M. Pena, J.M. Davis, S.J. Muga, J.A. Carson, Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R393–R401 (2008)PubMedCrossRef
30.
J. Batista, R.V.T. Santos, L.M. Cunha, K. Mattos, E.M. Oliveira, M.C.L. Seelaender, L.F.B.P. Costa Rosa, Changes in the pro-inflammatory cytokine production and peritoneal macrophage function in rats with chronic heart failure. Cytokine 34, 284–290 (2006)PubMedCrossRef
31.
M.A. Panaro, N. Gagliardi, C. Saponaro, R. Calvello, V. Mitolo, A. Cianciulli, Toll-like receptor 4 mediates LPS-induced release of nitric oxide and tumor necrosis factor-alpha by embryonal cardiomyocytes: biological significance and clinical implications in human pathology. Curr. Pharm. Des. 16, 766–774 (2010)PubMedCrossRef
32.
X.Q. Li, W. Cao, T. Li, A.G. Zeng, L.L. Hao, X.N. Zhang, Q.B. Mei, Amlodipine inhibits TNF-α production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway. Int. Immunopharmacol. 9, 1032–1041 (2009)PubMedCrossRef
33.
B.M. Meador, C.P. Krzyszton, R.W. Johnson, K.A. Huey, Effects of IL-10 and age on IL-6, IL-1beta, and TNF-α responses in mouse skeletal and cardiac muscle to an acute inflammatory insult. J. Appl. Physiol. 104, 991–997 (2008)PubMedCrossRef
34.
C.H. Lang, C. Silvis, N. Deshpande, G. Nystrom, R.A. Frost, Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1-beta, -6, and high-mobility-group protein-1 in skeletal muscle. Shock 19, 538–546 (2003)PubMedCrossRef
35.
A. Sandek, M. Rauchhaus, S.D. Anker, S. von Haehling, The emerging role of the gut in chronic heart failure. Curr. Opin. Clin. Nutr. Metab. Care 11, 632–639 (2008)PubMedCrossRef
36.
A. Sandek, J. Bauditz, A. Swidsinski, S. Buhner, J. Weber-Eibel, S. von Haehling, W. Schroedl, T. Karhausen, W. Doehner, M. Rauchhaus, P. Poole-Wilson, H.D. Volk, H. Lochs, S.D. Anker, Altered intestinal function in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1561–1569 (2007)PubMedCrossRef
37.
S. Genth-Zotz, S. von Haehling, A.P. Bolger, P.R. Kalra, R. Wensel, A.J.S. Coats, S.D. Anker, Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am. J. Cardiol. 90, 1226–1230 (2002)PubMedCrossRef
38.
Y.P. Li, M.B. Reid, NF-kB mediates the protein loss induced by TNF-α in differentiated skeletal muscle. Am. J. Physiol. 279, R1165–R1170 (2000)
39.
S.C. Kandarian, R.W. Jackman, Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 33, 155–165 (2006)PubMedCrossRef
40.
D. Cai, J.D. Frantz, N.E. Tawa, P.A. Melendez, B.C. Oh, H.G.W. Lidov, P.O. Hasselgren, W.R. Frontera, J. Lee, D.J. Glass, S.E. Shoelson, IKK[beta]/NF-[kappa]B activation causes severe muscle wasting in mice. Cell 119, 285–298 (2004)PubMedCrossRef
41.
M. Buck, M. Chojkier, Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J. 15, 1753–1765 (1996)PubMed
42.
J.M. Sacheck, A. Ohtsuka, S.C. McLary, A.L. Goldberg, IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Endocrinol. Metab. 287, E591–E601 (2004)PubMedCrossRef
43.
Y.P. Li, Y. Chen, J. John, J. Moylan, B. Jin, D.L. Mann, M.B. Reid, TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 19, 362–370 (2005)PubMedCrossRef
44.
E. Latres, A.R. Amini, A.A. Amini, J. Griffiths, F.J. Martin, Y. Wei, H.C. Lin, G.D. Yancopoulos, D.J. Glass, Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. 280, 2737–2744 (2005)PubMedCrossRef
45.
V. Adams, A. Linke, U. Wisloff, C. Doring, S. Erbs, N. Krankel, C.C. Witt, S. Labeit, U. Muller-Werdan, G. Schuler, R. Hambrecht, Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc. Res. 73, 120–129 (2007)PubMedCrossRef
46.
V. Adams, B. Nehrhoff, U. Späte, A. Linke, P.C. Schulze, A. Baur, S. Gielen, R. Hambrecht, G. Schuler, Induction of iNOS-expression in skeletal muscle by IL-1ß and NFκB activation: an in vitro and in vivo study. Cardiovasc. Res. 54, 95–104 (2002)PubMedCrossRef
47.
S. Di Marco, R. Mazroui, P. Dallaire, S. Chittur, S.A. Tenenbaum, D. Radzioch, A. Marette, I.E. Gallouzi, NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol. Cell. Biol. 25, 6533–6545 (2005)PubMedCrossRef
48.
B.M. Matata, M. Galinanes, Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor- + ¦B DNA binding activity. J. Biol. Chem. 277, 2330–2335 (2002)PubMedCrossRef
49.
S. Gielen, V. Adams, A. Linke, S. Erbs, S. M+Âbius-Winkler, A. Schubert, G. Schuler, R. Hambrecht, Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle. Eur. J. Cardiovasc. Prev. Rehabil. 12, 393–400 (2005)PubMedCrossRef
50.
51.
L. Dalla-Libera, R. Sabbadini, C. Renken, B. Ravara, M. Sandri, R. Betto, A. Angelini, G. Vescovo, Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-α and sphingosine. J. Mol. Cell. Cardiol. 33, 1871–1878 (2001)PubMedCrossRef
52.
G. Vescovo, L. Dalla-Libera, Skeletal muscle apoptosis in experimental heart failure: The only link between inflammation and skeletal muscle wastage? Curr. Opin. Clin. Nutr. Metab. Care 9, 416–422 (2006)PubMedCrossRef
53.
V. Adams, H. Jiang, J. Yu, S. Möbius-Winkler, E. Fiehn, A. Linke, C. Weigl, G. Schuler, R. Hambrecht, Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. 33, 959–965 (1999)PubMedCrossRef
54.
55.
V.M. Conraads, V.Y. Hoymans, T. Vermeulen, P. Beckers, N. Possemiers, M. De Maeseneer, C. Vrints, W. Martinet, Exercise capacity in chronic heart failure patients is related to active gene transcription in skeletal muscle and not apoptosis. Eur. J. Cardiovasc. Prev. Rehabil. 16, 325–332 (2009)PubMedCrossRef
56.
S. von Haehling, S.D. Anker, Future prospects of anticytokine therapy in chronic heart failure. Expert Opin. Investig. Drugs 14, 163–176 (2005)CrossRef
57.
D.L. Mann, J.J.V. McMurray, M. Packer, K. Swedberg, J.S. Borer, W.S. Colucci, J. Djian, H. Drexler, A. Feldman, L. Kober, H. Krum, P. Liu, M. Nieminen, L. Tavazzi, D.J. van Veldhuisen, A. Waldenstrom, M. Warren, A. Westheim, F. Zannad, T. Fleming, Targeted anticytokine therapy in patients with chronic heart failure. Circulation 109, 1594–1602 (2004)PubMedCrossRef
58.
S.D. Anker, A.J.S. Coats, How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. 86, 123–130 (2002)PubMedCrossRef
59.
E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, J.T. Willerson, ATTACH Investigators, Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α in patients with moderate-to-severe heart failure. Circulation 107, 3133–3140 (2003)PubMedCrossRef
60.
E.P. Sampaio, E.N. Sarno, R. Galilly, G. Kaplan, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699–703 (1991)PubMedCrossRef
61.
L. Gullestad, A.G. Semb, E. Holt, R. Skardal, T. Ueland, A. Yndestad, S.S. Froland, P. Aukrust, Effect of thalidomide in patients with chronic heart failure. Am. Heart J. 144, 847–850 (2002)PubMed
62.
L. Gullestad, J. Kiekshus, J.K. Damas, T. Ueland, A. Yndestad, P. Aukrust, Agents targeting inflammation in heart failure. Expert Opin. Investig. Drugs 14, 557–566 (2005)PubMedCrossRef
63.
I. Agoston, Z.I. Dibbs, F. Wang, G. Muller, J.B. Zeldis, D.L. Mann, B. Bozkurt, Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J. Card. Fail. 8, 306–314 (2002)PubMedCrossRef
64.
L. Gullestad, T. Ueland, J.G. Fjeld, E. Holt, T. Gundersen, K. Breivik, M. Folling, A. Hodt, R. Skardal, J. Kjekshus, A. Andreassen, E. Kjekshus, R. Wergeland, A. Yndestad, S.S. Froland, A.G. Semb, P. Aukrust, Effect of thalidomide on cardiac remodeling in chronic heart failure. Circulation 112, 3408–3414 (2005)PubMedCrossRef
65.
CONSENSUS Trail Study Group, Effects of enalapril on morbidity and mortality in severe congestive heart failure. N. Engl. J. Med. 316, 1429–1431 (1987)
66.
SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 (1991)
67.
M.A. Pfeffer, E. Braunwald, L.A. Moye, Effects of captopril on mortality and morbidity in patients with left ventricular dysfunktion after myocardial infarction. Result of the survival and ventricular enlargement trail. N. Engl. J. Med. 327, 669–677 (1992)PubMedCrossRef
68.
Y.H. Song, Y. Li, J. Du, W.E. Mitch, N. Rosenthal, P. Delafontaine, Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115, 451–458 (2005)PubMed
69.
B.M. Rezk, T. Yoshida, L. Semprun-Prieto, Y. Higashi, S. Sukhanov, P. Delafontaine, Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS ONE 7, e30276 (2012)PubMedCrossRef
70.
S.T. Russell, P.M. Sanders, M.J. Tisdale, Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231, 290–294 (2006)PubMedCrossRef
71.
S.T. Russell, S.M. Wyke, M.J. Tisdale, Mechanism of induction of muscle protein degradation by angiotensin II. Cell. Signal. 18, 1087–1096 (2006)PubMedCrossRef
72.
T. Yoshida, L. Semprun-Prieto, S. Sukhanov, P. Delafontaine, IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am. J. Physiol. Heart Circ. Physiol. 298, H1565–H1570 (2010)PubMedCrossRef
73.
S.D. Anker, A. Negassa, A.J. Coats, R. Afzal, P.A. Poole-Wilson, J.N. Cohn, S. Yusuf, Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361, 1077–1083 (2003)PubMedCrossRef
74.
G.D. Schellenbaum, N.L. Smith, S.R. Heckbert, T. Lumley, T.D. Rea, C.D. Furberg, M.F. Lyles, B.M. Psaty, Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J. Am. Geriatr. Soc. 53, 1996–2000 (2005)PubMedCrossRef
75.
M. Di Bari, L. Van De Poll-Franse, G. Onder, S.B. Kritchevsky, A. Newman, T.B. Harris, J.D. Williamson, N. Marchionni, M. Pahor, Antihypertensive medications and differences in muscle mass in older persons: the health, aging and body composition study. J. Am. Geriatr. Soc. 52, 961–966 (2004)PubMedCrossRef
76.
E.T. Poehlman, E. Danforth, Endurance training increases metabolic rate and norepinephrine appearance rate in older individuals. Am. J. Physiol. Endocrinol. Metab. 261, E233–E239 (1991)
77.
S.D. Anker, T.P. Chua, P. Ponikowski, D. Harrington, J.W. Swan, W.J. Kox, P.A. Poole-Wilson, A.J.S. Coats, Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96, 526–534 (1997)PubMedCrossRef
78.
T.O. Obisesan, M.J. Toth, K. Donaldson, S.S. Gottlieb, M.L. Fisher, P. Vaitekevicius, E.T. Poehlman, Energy expenditure and symptom severity in men with heart failure. Am. J. Cardiol. 77, 1250–1252 (1996)PubMedCrossRef
79.
I.S. Anand, R. Ferrari, G.S. Kalra, P.L. Wahi, P.A. Poole-Wilson, P.C. Harris, Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 80, 299–305 (1989)PubMedCrossRef
80.
81.
A.C. McPherron, A.M. Lawler, S.J. Lee, Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nature 387, 83–90 (1997)PubMedCrossRef
82.
A.C. McPherron, S.J. Lee, Double muscling in cattle due to mutations in the myostatin gene. Proc. Natl. Acad. Sci. USA 94, 12457–12461 (1997)PubMedCrossRef
83.
M. Schuelke, K.R. Wagner, L.E. Stolz, C. Hubner, T. Riebel, W. Komen, T. Braun, J.F. Tobin, S.J. Lee, Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350, 2682–2688 (2004)PubMedCrossRef
84.
N.F. Gonzales-Cadavid, W.E. Taylor, K. Yaresheski, I. Sinha-Hikim, K. Ma, S. Ezzat, R. Shen, R. Lalani, S. Asa, M. Mamita, G. Nair, S. Arver, S. Bhasin, Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA 95, 14938–14943 (1998)CrossRef
85.
K.E. Yarasheski, S. Bhasin, I. Sinha-Hikim, J. Pak-Loduca, N.F. Gonzales-Cadavid, Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J. Nutr. Health Aging 6, 343–348 (2002)PubMed
86.
K. Lenk, R. Schur, A. Linke, S. Erbs, Y. Matsumoto, V. Adams, G. Schuler, Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. 11, 342–348 (2009)PubMedCrossRef
87.
T.A. Zimmers, M.V. Davies, L.G. Koniaris, P. Haynes, A.F. Esquela, K.N. Tomkinson, A.C. McPherron, N.M. Wolfman, S.J. Lee, Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486–1488 (2002)PubMedCrossRef
88.
A. Rebbapragada, H. Benchabane, J.L. Wrana, A.J. Celeste, L. Attisano, Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23, 7230–7242 (2003)PubMedCrossRef
89.
S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 89, 127–138 (1997)PubMedCrossRef
90.
M. Maroto, R. Reshef, A.E. Münsterberg, S. Koester, M. Goulding, A.B. Lassar, Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89, 139–148 (1997)PubMedCrossRef
91.
B. Langley, M. Thomas, A. Bishop, M. Sharma, S. Gilmour, R. Kambadur, Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem. 277, 49831–49840 (2002)PubMedCrossRef
92.
C. McFarlane, A. Hennebry, M. Thomas, E. Plummer, N. Ling, M. Sharma, R. Kambadur, Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp. Cell Res. 314, 317–329 (2008)PubMedCrossRef
93.
D.L. Allen, T.G. Unterman, Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am. J. Physiol. Cell Physiol. 292, C188–C199 (2007)PubMedCrossRef
94.
H. Amthor, G. Nicholas, I. McKinnell, C.F. Kemp, M. Sharma, R. Kambadur, K. Patel, Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev. Biol. 270, 19–30 (2004)PubMedCrossRef
95.
S.J. Lee, Y.S. Lee, T.A. Zimmers, A. Soleimani, M.M. Matzuk, K. Tsuchida, R.D. Cohn, E.R. Barton, Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 24, 1998–2008 (2010)PubMedCrossRef
96.
M.M. Matzuk, N. Lu, H. Vogel, K. Sellheyer, D.R. Roop, A. Bradley, Multiple defects and perinatal death in mice deficient in follistatin. Nature 374, 360–363 (1995)PubMedCrossRef
97.
S. Bogdanovich, T.O.B. Krag, E.R. Barton, L.D. Morris, L.A. Whittemore, R.S. Ahima, T.S. Khurana, Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418–421 (2002)PubMedCrossRef
98.
L.A. Whittemore, K. Song, X. Li, J. Aghajanian, M. Davies, S. Girgenrath, J.J. Hill, M. Jalenak, P. Kelley, A. Knight, R. Maylor, D. O`Hara, A. Pearson, A. Quazi, S. Ryerson, X.Y. Tan, K.N. Tomkinson, G.M. Veldman, A. Widom, J.F. Wright, S. Wudyka, L. Zhao, N.M. Wolfman, Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 300, 965–971 (2003)PubMedCrossRef
99.
K.R. Wagner, J.L. Fleckenstein, A.A. Amato, R.J. Barohn, K. Bushby, D.M. Escolar, K.M. Flanigan, A. Pestronk, R. Tawil, G.I. Wolfe, M. Eagle, J.M. Florence, W.M. King, S. Pandya, V. Straub, P. Juneau, K. Meyers, C. Csimma, T. Araujo, R. Allen, S.A. Parsons, J.M. Wozney, E.R. LaVallie, J.R. Mendell, A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 63, 561–571 (2008)PubMedCrossRef
100.
X. Zhou, J.L. Wang, J. Lu, Y. Song, K.S. Kwak, Q. Jiao, R. Rosenfeld, Q. Chen, T. Boone, W.S. Simonet, D.L. Lacey, A.L. Goldberg, H.Q. Han, Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531–543 (2010)PubMedCrossRef
101.
L. Zhang, V. Rajan, E. Lin, Z. Hu, H.Q. Han, X. Zhou, Y. Song, H. Min, X. Wang, J. Du, W.E. Mitch, Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 25, 1653–1663 (2011)PubMedCrossRef
102.
J.M.P. Holly, C.M. Perks, C.E.H. Stewart, Overview of insulin-like growth factor physiology. Growth Horm. IGF Res. 10, S8–S9 (2000)PubMedCrossRef
103.
104.
N.J. Szewczyk, L.A. Jacobson, Signal-transduction networks and the regulation of muscle protein degradation. Int. J. Biochem. Cell Biol. 37, 1997–2011 (2005)PubMedCrossRef
105.
S. Watanabe, T. Tamura, K. Ono, H. Horiuchi, T. Kimura, T. Kita, Y. Furukawa, Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur. J. Heart Fail. 12, 1214–1222 (2010)PubMedCrossRef
106.
S.D. Lee, L.M. Chen, W.W. Kuo, W.T. Shu, W.H. Kuo, E.J. Huang, C.C. Tsai, P.C. Li, J.Y. Liu, T.H. Chen, C.Y. Huang, Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Clin. Chim. Acta 367, 62–68 (2006)PubMedCrossRef
107.
C. Rommel, S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, T.N. Stitt, G.D. Yancopoulos, D.J. Glass, Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009–1013 (2001)PubMedCrossRef
108.
T. Matsui, T. Nagoshi, A. Rosenzweig, Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2, 20–223 (2003)CrossRef
109.
C. Buechler, J. Wanninger, M. Neumeier, Adiponectin receptor binding proteins—recent advances in elucidating adiponectin signalling pathways. FEBS Lett. 584, 4280–4286 (2010)
110.
M. Sandri, C. Sandri, A. Gilbert, C. Skurk, E. Calabria, A. Picard, K. Walsh, S. Schiaffino, S.H. Lecker, A.L. Goldberg, FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399–412 (2004)PubMedCrossRef
111.
M. Sandri, J. Lin, C. Handschin, W. Yang, Z.P. Arany, S.H. Lecker, A.L. Goldberg, B.M. Spiegelman, PGC-1α¦ protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA 103, 16260–16265 (2006)PubMedCrossRef
112.
R. Bassel-Duby, E.N. Olson, Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 75, 19–37 (2006)PubMedCrossRef
113.
C.M. Liu, Z. Yang, C.W. Liu, R. Wang, P. Tien, R. Dale, L.Q. Sun, Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 14, 945–952 (2007)PubMedCrossRef
114.
S. Genth-Zotz, R. Zotz, S. Geil, T. Voigtländer, J. Meyer, H. Darius, Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 99, 18–21 (1999)PubMedCrossRef
115.
S. Fazio, D. Sabatini, B. Capaldo, C. Vigorito, A. Giordano, R. Guida, F. Pardo, B. Biondi, L. Sacc+á, A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 334, 809–814 (1996)PubMedCrossRef
116.
K.J. Osterziel, O. Strohm, J. Schuler, M. Friedrich, D. Hänlein, R. Willenbrock, S.D. Anker, P. Poole-Wilson, M.B. Ranke, R. Dietz, Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351, 1233–1237 (1998)PubMedCrossRef
117.
J. Isgaard, C.H. Bergh, K. Caidahl, M. Lomsky, A. Hjalmarson, B.A. Bengtsson, A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J. 19, 1704–1711 (1998)PubMedCrossRef
118.
J. Takala, E. Ruokonen, N.R. Webster, M.S. Nielsen, D.F. Zandstra, G. Vundelinckx, C.J. Hinds, Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785–792 (1999)PubMedCrossRef
119.
R.C. Cuneo, P. Wilmshurst, C. Lowy, G. Mcgauley, P.H. Sönksen, Cardiac failure responding to growth hormone. Lancet 333, 838–839 (1989)CrossRef
120.
J.G. O′Driscoll, D.J. Green, M. Ireland, D. Kerr, R.L. Larbalestier, Treatment of end-stage cardiac failure with growth hormone. Lancet 349, 1068 (1997)PubMedCrossRef
121.
C.J. Bagatell, W.J. Bremner, Androgens in men—uses and abuses. N. Engl. J. Med. 334, 707–715 (1996)PubMedCrossRef
122.
123.
H.A. Feldman, C. Longcope, C.A. Derby, C.B. Johannes, A.B. Araujo, A.D. Coviello, W.J. Bremner, J.B. McKinlay, Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 87, 589–598 (2002)PubMedCrossRef
124.
A.B. O′Donnell, T.G. Travison, S.S. Harris, J.L. Tenover, J.B. McKinlay, Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 91, 425–431 (2006)PubMedCrossRef
125.
E.A. Jankowska, B. Biel, J. Majda, A. Szklarska, M. Lopuszanska, M. Medras, S.D. Anker, W. Banasiak, P.A. Poole-Wilson, P. Ponikowski, Anabolic deficiency in men with chronic heart failure. Circulation 114, 1829–1837 (2006)PubMedCrossRef
126.
127.
E.A. Jankowska, G. Filippatos, B. Ponikowska, L. Borodulin-Nadzieja, S.D. Anker, W. Banasiak, P.A. Poole-Wilson, P. Ponikowski, Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J. Card. Fail. 15, 442–450 (2009)PubMedCrossRef
128.
G. Güder, S. Frantz, J. Bauersachs, B. Allolio, G. Ertl, C.E. Angermann, S. Störk, Low circulating androgens and mortality risk in heart failure. Heart 96, 504–509 (2010)PubMedCrossRef
129.
E. Wehr, S. Pilz, B.O. Boehm, W. März, T. Grammer, B. Obermayer-Pietsch, Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur. J. Heart Fail. 13, 482–488 (2011)PubMedCrossRef
130.
G. Caminiti, M. Volterrani, F. Iellamo, G. Marazzi, R. Massaro, M. Miceli, C. Mammi, M. Piepoli, M. Fini, G.M.C. Rosano, Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919–927 (2009)PubMedCrossRef
131.
M. Toma, F.A. McAlister, E.E. Coglianese, V. Vidi, S. Vasaiwala, J.A. Bakal, P.W. Armstrong, J.A. Ezekowitz, Testosterone supplementation in heart failure/clinical perspective. Circ. Heart Fail. 5, 315–321 (2012)PubMedCrossRef
132.
S. Bhasin, T.W. Storer, M. Javanbakht, N. Berman, K.E. Yarasheski, J. Phillips, M. Dike, I. Sinha-Hikim, R. Shen, R.D. Hays, G. Beall, Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283, 763–770 (2000)PubMedCrossRef
133.
Ss. Yeh, B. DeGuzman, T. Kramer, Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 122, 421–428 (2002)PubMedCrossRef
134.
E. O′Neill, J. Wilding, C. Kahn, H. Van Remmen, A. McArdle, M. Jackson, G. Close, Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. AGE 32, 209–222 (2010)PubMedCrossRef
135.
A.A. Sayer, H.E. Syddall, E.M. Dennison, H.J. Martin, D.I.W. Phillips, C. Cooper, C.D. Byrne, Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. QJM 100, 707–713 (2007)PubMedCrossRef
136.
S.W. Lee, G.H. Park, S.W. Lee, J.H. Song, K.C. Hong, M.J. Kim, Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol. Dial. Transplant. 22, 2554–2562 (2007)PubMedCrossRef
137.
P. Daneryd, L. Hafström, E. Svanberg, I. Karlberg, Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats. Eur. J. Cancer 31A, 97–103 (1995)PubMedCrossRef
138.
E. Ingelsson, J. Sundström, J. Arnlöv, B. Zethelius, L. Lind, Insulin resistance and risk of congestive heart failure. JAMA 294, 334–341 (2005)PubMedCrossRef
139.
Y. Ohta, S. Kinugawa, S. Matsushima, T. Ono, M.A. Sobirin, N. Inoue, T. Yokota, K. Hirabayashi, H. Tsutsui, Oxidative stress impairs insulin signal in skeletal muscle and causes insulin resistance in postinfarct heart failure. Am. J. Physiol. Heart Circ. Physiol. 300, H1637–H1644 (2011)PubMedCrossRef
140.
G.A. Nader, Molecular determinants of skeletal muscle mass: getting the “AKT” together. Int. J. Biochem. Cell Biol. 37, 1985–1996 (2005)PubMedCrossRef
141.
C. Guillet, Y. Boirie, Insulin resistance: a contributing factor to age-related muscle mass loss. Diabetes Metab. 31, 5820–5826 (2005)CrossRef
142.
K. Takaya, H. Ariyasu, N. Kanamoto, H. Iwakura, A. Yoshimoto, M. Harada, K. Mori, Y. Komatsu, T. Usui, A. Shimatsu, Y. Ogawa, K. Hosoda, T. Akamizu, M. Kojima, K. Kangawa, K. Nakao, Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab. 85, 4908–4911 (2000)PubMedCrossRef
143.
E. Arvat, M. Maccario, L. Di Vito, F. Broglio, A. Benso, C. Gottero, M. Papotti, G. Muccioli, C. Dieguez, F.F. Casanueva, R. Deghenghi, F. Camanni, E. Ghigo, Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J. Clin. Endocrinol. Metab. 86, 1169–1174 (2001)PubMedCrossRef
144.
D.E. Cummings, Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol. Behav. 89, 71–84 (2006)PubMedCrossRef
145.
C. Ledderose, S. Kreth, A. Beiras-Fernandez, Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function. Recent Pat. Endocr. Metab. Immune Drug Discov. 5, 1–6 (2012)CrossRef
146.
N. Nagaya, J. Moriya, Y. Yasumura, M. Uematsu, F. Ono, W. Shimizu, K. Ueno, M. Kitakaze, K. Miyatake, K. Kangawa, Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 3674–3679 (2004)PubMedCrossRef
147.
Y.J. Akashi, J. Springer, S.D. Anker, Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr. Heart Fail. Rep. 2, 198–203 (2005)PubMedCrossRef
148.
S. Palus, R. Schur, Y.J. Akashi, B. Bockmeyer, R. Datta, H. Halem, J. Dong, M.D. Culler, V. Adams, S.D. Anker, J. Springer, Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One, e26865 (2011)
149.
Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994)PubMedCrossRef
150.
S. Kamohara, R. Burcelin, J.L. Halaas, J.M. Friedman, M.J. Charron, Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389, 374–377 (1997)PubMedCrossRef
151.
S. Margetic, C. Gazzola, G.G. Pegg, R.A. Hill, Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 26, 1407–1433 (2002)PubMedCrossRef
152.
R.S. Ahima, D.A. Antwi, Brain regulation of appetite and satiety. Endocrinol. Metab. Clin. North Am. 37, 811–823 (2008)PubMedCrossRef
153.
F. Leyva, S.D. Anker, K. Egerer, J.C. Stevenson, W.J. Kox, A.J.S. Coats, Hyperleptinaemia in chronic heart failure. Eur. Heart J. 19, 1547–1551 (1998)PubMedCrossRef
154.
G.S. Filippatos, K. Tsilias, K. Venetsanou, E. Karambinos, D. Manolatos, A. Kranidis, J. Antonellis, F. Kardaras, L. Anthopoulos, G. Baltopoulos, Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system. Int. J. Cardiol. 76, 117–122 (2000)PubMedCrossRef
155.
W. Doehner, C.D. Pflaum, M. Rauchhaus, I.F. Godsland, K. Egerer, M. Cicoira, V.G. Florea, R. Sharma, A.P. Bolger, A.J. Coats, S.D. Anker, C.J. Strasburger, Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur. J. Endocrinol. 145, 727–735 (2001)PubMedCrossRef
156.
P.C. Schulze, J. Kratzsch, Leptin as a new diagnostic tool in chronic heart failure. Clin. Chim. Acta 362, 1–11 (2005)PubMedCrossRef
157.
P.C. Schulze, J. Kratzsch, A. Linke, N. Schoene, V. Adams, S. Gielen, S. Erbs, S. Moebius-Winkler, G. Schuler, Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur. J. Heart Fail. 5, 33–40 (2003)PubMedCrossRef
158.
M.W. Nickola, L.E. Wold, P.B. Colligan, G.J. Wang, W.K. Samson, J. Ren, Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO. Hypertension 36, 501–505 (2000)PubMedCrossRef
159.
K.R. McGaffin, C.S. Moravec, C.F. McTiernan, Leptin signaling in the failing and mechanically unloaded human heart/CLINICAL PERSPECTIVE. Circ. Heart Fail. 2, 676–683 (2009)PubMedCrossRef
160.
M.W. Hamrick, C. Pennington, D. Newton, D. Xie, C. Isales, Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34, 376–383 (2004)PubMedCrossRef
161.
S.A. Warmington, R. Tolan, S. McBennett, Functional and histological characteristics of skeletal muscle and the effects of leptin in the genetically obese (ob/ob) mouse. Int. J. Obes. Relat. Metab. Disord. 24, 1040–1050 (2000)PubMedCrossRef
162.
M.W. Hamrick, S. Herberg, P. Arounleut, H.Z. He, A. Shiver, R.Q. Qi, L. Zhou, C.M. Isales, Q.S. Mi, The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged mice. Biochem. Biophys. Res. Commun. 400, 379–383 (2010)PubMedCrossRef
163.
Y.Z. Wang, Y.N. Huang, K.Y. Sun, J.H. Qi, L. Xiang, Leptin gene transfer regulates fibromuscular development and lipid deposition in muscles via SIRT1, FOXO3a and PGC-1α in mice in vivo. Int. J. Mol. Med. 28, 617–623 (2011)PubMed
164.
K. Maeda, K. Okubo, I. Shimomura, K. Mizuno, Y. Matsuzawa, K. Matsubara, Analysis of an expression profile of genes in the human adipose tissue. Gene 190, 227–235 (1997)PubMedCrossRef
165.
Y. Okamoto, S. Kihara, N. Ouchi, M. Nishida, Y. Arita, M. Kumada, K. Ohashi, N. Sakai, I. Shimomura, H. Kobayashi, N. Terasaka, T. Inaba, T. Funahashi, Y. Matsuzawa, Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106, 2767–2770 (2002)PubMedCrossRef
166.
C. Kobashi, M. Urakaze, M. Kishida, E. Kibayashi, H. Kobayashi, S. Kihara, T. Funahashi, M. Takata, R. Temaru, A. Sato, K. Yamazaki, N. Nakamura, M. Kobayashi, Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res. 97, 1245–1252 (2005)PubMedCrossRef
167.
W. Koenig, N. Khuseyinova, J. Baumert, C. Meisinger, H. Löwel, Serum concentrations of adiponectin and risk of type 2 Diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-Year follow-up of a large cohort from southern Germany. J. Am. Coll. Cardiol. 48, 1369–1377 (2006)PubMedCrossRef
168.
J.M. Bruun, A.S. Lihn, C. Verdich, S.B. Pedersen, S. Toubro, A. Astrup, B. Richelsen, Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 285, E527–E533 (2003)PubMed
169.
S.T. Gulen, F. Karadag, A.B. Karul, N. Kilicarslan, E. Ceylan, N.K. Kuman, O. Cildag, Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung 190, 327–332 (2012)PubMedCrossRef
170.
C. Kistorp, J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg, P. Hildebrandt, Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112, 1756–1762 (2005)PubMedCrossRef
171.
J. George, S. Patal, D. Wexler, Y. Sharabi, E. Peleg, Y. Kamari, E. Grossman, D. Sheps, G. Keren, A. Roth, Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92, 1420–1424 (2006)PubMedCrossRef
172.
T. Tamura, Y. Furukawa, R. Taniguchi, Y. Sato, K. Ono, H. Horiuchi, Y. Nakagawa, T. Kita, T. Kimura, Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ. J. 71, 623–630 (2007)PubMedCrossRef
173.
M.B. McEntegart, B. Awede, M.C. Petrie, N. Sattar, F.G. Dunn, N.G. MacFarlane, J.J.V. McMurray, Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 28, 829–835 (2007)PubMedCrossRef
174.
J. Fruebis, T.S. Tsao, S. Javorschi, D. Ebbets-Reed, M.R. Erickson, F.T. Yen, B.E. Bihain, H.F. Lodish, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA 98, 2005–2010 (2001)PubMedCrossRef
175.
Y. Qi, N. Takahashi, S.M. Hileman, H.R. Patel, A.H. Berg, U.B. Pajvani, P.E. Scherer, R.S. Ahima, Adiponectin acts in the brain to decease body weight. Nat. Med. 10, 524–529 (2004)PubMedCrossRef
176.
An.M. Van Berendoncks, P. Beckers, V.Y. Hoymans, N. Possemiers, F.L. Wuyts, C.J. Vrints, V.M. Conraads, Exercise training reduces circulating adiponectin levels in patients with chronic heart failure. Clin. Sci. 118, 281–289 (2010)PubMedCrossRef
177.
S. Adamopoulos, J. Parissis, C. Kroupis, M. Georgiadis, D. Karatzas, G. Karavolias, K. Koniavitou, A.J.S. Coats, D.Th. Kremastinos, Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur. Heart J. 22, 791–797 (2001)PubMedCrossRef
178.
N.A. Smart, A.I. Larsen, J.P. Le Maitre, A.S. Ferraz, Effect of exercise training on interleukin-6, tumour necrosis factor alpha and functional capacity in heart failure. Cardiol. Res. Pract. 2011, 532620 (2011)PubMed
179.
S. Gielen, V. Adams, S. Möbius-Winkler, A. Linke, S. Erbs, J. Yu, W. Kempf, A. Schubert, G. Schuler, R. Hambrecht, Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J. Am. Coll. Cardiol. 42, 861–868 (2003)PubMedCrossRef
180.
J. Batista, J.C. Rosa, R.D. Lopes, F.S. Lira, J. Martins, A.S. Yamashita, P.C. Brum, J. Lancha, A.C. Lopes, M. Seelaender, Exercise training changes IL-10/TNF-[alpha] ratio in the skeletal muscle of post-MI rats. Cytokine 49, 102–108 (2010)PubMedCrossRef
181.
A. Linke, V. Adams, P.C. Schulze, S. Erbs, S. Gielen, E. Fiehn, S. Möbius-Winkler, A. Schubert, G. Schuler, R. Hambrecht, Antioxidative effects of exercise training in patients with chronic heart failure. Increase in radical scavenger enzyme activity in skeletal muscle. Circulation 111, 1763–1770 (2005)PubMedCrossRef
182.
S. Gielen, M. Sandri, I. Kozarez, J. Kratsch, D. Teupser, J. Thiery, S. Erbs, N. Mangner, K. Lenk, R. Hambrecht, G. Schuler, V. Adams, Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized leipzig exercise intervention in chronic heart failure and aging (LEICA) catabolism study. Circulation 125, 2716–2727 (2012)
183.
R. Höllriegel, E.B. Beck, A. Linke, V. Adams, S. Möbius-Winkler, N. Mangner, M. Sandri, S. Gielen, M. Gutberlet, R. Hambrecht, G. Schuler, S. Erbs, Anabolic effects of exercise training in patients with advanced chronic heart failure (NYHA IIIb): impact on ubiquitin-protein ligases expression and skeletal muscle size. Int. J. Cardiol., (2012)
184.
S. Fujita, T. Abe, M.J. Drummond, J.G. Cadenas, H.C. Dreyer, Y. Sato, E. Volpi, B.B. Rasmussen, Blood flow restriction during low-intensity resistance exercise increases S6K1 phosphorylation and muscle protein synthesis. J. Appl. Physiol. 103, 903–910 (2007)PubMedCrossRef
185.
K. Baar, K. Esser, Phosphorylation of p70S6k correlates with increased skeletal muscle mass following resistance exercise. Am. J. Physiol. Cell Physiol. 276, C120–C127 (1999)
186.
R. Hambrecht, P.C. Schulze, S. Gielen, A. Linke, S. Möbius-Winkler, S. Erbs, J. Kratzsch, A. Schubert, V. Adams, G. Schuler, Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur. J. Cardiovasc. Prev. Rehabil. 12, 401–416 (2005)PubMedCrossRef
Metadata
Title
Cachexia in chronic heart failure: endocrine determinants and treatment perspectives
Authors
Norman Mangner
Yae Matsuo
Gerhard Schuler
Volker Adams
Publication date
01-04-2013
Publisher
Springer US
Published in
Endocrine / Issue 2/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9767-z

Other articles of this Issue 2/2013

Endocrine 2/2013 Go to the issue

Original Article

The effects of sonographic and demographic features and needle size on obtaining adequate cytological material in sonography-guided fine-needle aspiration biopsy of thyroid nodules

Letter to the Editor

Morphometric characteristics, cell proliferation parameters and apoptosis indices do not correlate with tendency to relapse in non-functioning pituitary macroadenomas

Letter to the Editor

Bilateral intrathyroidal hemorrhage after fine needle aspiration completely resolved by compression without thyroidectomy

Research Letter

Changes in adipokines but not in body composition after one week of prednisone intake in physically fit women

Review

Erectile dysfunction as a cardiovascular risk factor in patients with diabetes

Review

Hormones as doping in sports
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits